<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03471507</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00081546</org_study_id>
    <nct_id>NCT03471507</nct_id>
  </id_info>
  <brief_title>Bonipar for Acute and Chronic Musculoskeletal Pain</brief_title>
  <official_title>Efficacy of a Topical Pain Relief Spray Containing Herbal Oil Extracts (Bonipar) Among Individuals With Acute and Chronic Musculoskeletal Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Winston Parris, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a non-inferiority study comparing efficacy and onset of action between the&#xD;
      herbal extracts topical solution, Bonipar, and diclofenac sodium topical solution, diclofenac&#xD;
      topical solution 1.5%.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a non-inferiority study comparing efficacy and onset of action between the&#xD;
      herbal extracts topical solution, Bonipar, and diclofenac sodium topical solution, diclofenac&#xD;
      topical solution 1.5% (approved by the FDA as a topical analgesic). Approximately 168 Duke&#xD;
      patients will be recruited from Duke Pain Clinic, and selected Duke primary care practices.&#xD;
      Individuals who report acute (less than 3 months duration) or chronic musculoskeletal pain of&#xD;
      any intensity will be considered for enrollment into the study. After obtaining consent,&#xD;
      eligible subjects will be will be randomized to receive Bonipar or diclofenac topical&#xD;
      solution 1.5%.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized to one of two study groups (Bonipar or diclofenac topical solution 1.5%), utilizing a predetermined randomization schedule in a 1:1 ratio.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The bottles will be labelled by pharmacy either &quot;Drug A&quot; or Drug B&quot; according to their designation with a label affixed to cover any drug manufacturing labeling. Only the dispensing pharmacy will not be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change over time of SPIR pain score from 24 hours prior to signing consent to 1 week after administration of study drug or active comparator</measure>
    <time_frame>Change of reported pain from approximately 24 hours before consent to approximately 1 week post administration of study drug (or comparator)</time_frame>
    <description>Subjective Pain Intensity Rating (SPIR) will be used, a patient-reported graduated scale where 0 = no pain and 10 = the maximum pain imaginable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Effects/Complications</measure>
    <time_frame>Up to approximately 1 week</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Time of Onset of Action of Bonipar measurement</measure>
    <time_frame>Up to 1 hour</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Chronic Pain</condition>
  <condition>Musculoskeletal Pain</condition>
  <arm_group>
    <arm_group_label>Bonipar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Diclofenac topical solution 1.5%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bonipar</intervention_name>
    <description>Apply 2 pumps 2 times a day to be applied topically on the affected area during a two week treatment period.</description>
    <arm_group_label>Bonipar</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac sodium topical solution 1.5%</intervention_name>
    <description>Apply 2 pumps 2 times a day to be applied topically on the affected area during a two week treatment period.</description>
    <arm_group_label>Diclofenac topical solution 1.5%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSIONARY CRITERIA:&#xD;
&#xD;
          -  Subject with acute and chronic localized musculoskeletal pain&#xD;
&#xD;
          -  Ages 18 to 80 years&#xD;
&#xD;
          -  Subjects of all races, gender or ethnic groups&#xD;
&#xD;
          -  Female subjects of childbearing age must have a negative pregnancy test Female&#xD;
             subjects of childbearing age who are sexually active must agree to use appropriate&#xD;
             contraceptive measures for the duration of the study. Medically acceptable&#xD;
             contraceptives include: (1) surgical sterilization (such as tubal ligation or&#xD;
             hysterectomy), (2) approved hormonal contraceptives (such as birth control pills,&#xD;
             patches, implants or injections), (3) barrier methods (such as a condom or diaphragm)&#xD;
             used with a spermicide, or (4) an intrauterine device (IUD).&#xD;
&#xD;
          -  Willing to provide written informed consent&#xD;
&#xD;
          -  Patients taking opioid or NSAID for their musculoskeletal pain may be included if pain&#xD;
             is inadequately controlled&#xD;
&#xD;
        EXCLUSIONARY CRITERIA:&#xD;
&#xD;
          -  Patients meeting any of the following criteria will be excluded from the study: Use&#xD;
             within 3 days of any topical agents on the affected area&#xD;
&#xD;
          -  Subject with active skin lesions or skin disease or with cutaneous manifestations of&#xD;
             systemic illnesses&#xD;
&#xD;
          -  Subject with history of uncontrolled diabetes (A1C of more than 9)&#xD;
&#xD;
          -  Subject with history of uncontrolled hypertension (SBP &gt; 160 and DBP &gt; 95)&#xD;
&#xD;
          -  Subject with active uncontrolled GERD (defined as more than 2 episodes per week) or&#xD;
             history of peptic ulcer disease&#xD;
&#xD;
          -  Subject with active cancer, spinal cord lesions or spine surgery&#xD;
&#xD;
          -  Subject with allergies to diclofenac or to other non-steroid anti-inflammatory drugs&#xD;
             (NSAID)&#xD;
&#xD;
          -  Known allergies to any oils, methyl salicylate and/or camphor&#xD;
&#xD;
          -  Subject is pregnant or lactating&#xD;
&#xD;
          -  Subject with history of heart attack, stroke or blood clot, or recent coronary artery&#xD;
             bypass graft surgery (CABG) (i.e., within the last six months)&#xD;
&#xD;
          -  Subject with history of alcohol or drug abuse within 1 year&#xD;
&#xD;
          -  Subject with history of severe cardiac, liver or kidney disease or any other medical&#xD;
             condition that may interfere with the subject's ability to participate in the study as&#xD;
             determined by the Investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lance Roy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lance Roy, MD</last_name>
    <phone>919-286-6938</phone>
    <email>sarah.a.hill@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alicja Szydlowska</last_name>
    <phone>+1 919 681 4377</phone>
    <email>alicja.szydlowska@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lance Roy, MD</last_name>
      <email>sarah.a.hill@duke.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 14, 2018</study_first_submitted>
  <study_first_submitted_qc>March 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2018</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Winston Parris, MD</investigator_full_name>
    <investigator_title>Professor Emeritus</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Musculoskeletal Pain</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

